Effect of Xuebijing Injection Combined with Ulinastatin Injection in the Treatment of Sepsis Complicated with Acute Lung Injury and Its Effect on HMGB1/TLR4/NF-κB Signaling Pathway
Objective To investigate the clinical effect of Xuebijing injection combined with Ulinastatin injection in the treatment of sepsis complicated with acute lung injury and their effect on high mobility group protein B1(HMGB1)/Toll-like receptor 4(TLR4)/nuclear factor-κB(NF-κB)signaling pathway.Methods In total,140 patients with sepsis compli-cated with acute lung injury who received treatment from January to December 2022 were divided into research group(n =70)and control group(n =70)by random number table method.Both groups received basic treatment according to the guidelines.On this basis,the research group was treated with Xuebijing injection combined with Ulinastatin injection,and the control group was treated with Xuebijing injection.The course of treatment in both groups was 2 weeks.The clinical efficacy,serum HMGB1,TLR4 and NF-κB levels,levels of serum inflammatory factors before and after treatment were compared between the two groups,and adverse reactions were recorded in the two groups.Results After treatment,the total effective rate of the re-search group was 91.43%(64/70),which was better than that of the control group(75.71%)(53/70)(P<0.05).After treatment,serum levels of HMGB1,TLR4,NF-κB,hypersensitive C reactive protein,tumor necrosis factor-α and procalcito-nin in the two groups were decreased,which were lower in the research group than in the control group(P<0.05,P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Xuebijing injection combined with Ulinastatin injection has good clinical effect in the treatment of patients with sepsis complicated with acute lung injury,which can effectively reduce the levels of serum HMGB1,TLR4,NF-κB and in-flammatory factors,with high safety.
SepsisAcute lung injuryXuebijing injectionUlinastatin injectionHigh mobility group protein B1Toll-like receptor 4NF-kappa BHypersensitive C reactive protein
万方数据
维普
